- Home
- OPTN vs BOLD Comparison
OPTN vs BOLD Comparison
Compare OPTN & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPTN
- BOLD
- Stock Information
- Founded
- OPTN 2010
- BOLD 2018
- Country
- OPTN United States
- BOLD United States
- Employees
- OPTN N/A
- BOLD N/A
- Industry
- OPTN Biotechnology: Pharmaceutical Preparations
- BOLD
- Sector
- OPTN Health Care
- BOLD
- Exchange
- OPTN Nasdaq
- BOLD Nasdaq
- Market Cap
- OPTN 92.8M
- BOLD 30.3M
- IPO Year
- OPTN 2017
- BOLD 2024
- Fundamental
- Price
- OPTN $9.39
- BOLD $1.50
- Analyst Decision
- OPTN Hold
- BOLD Hold
- Analyst Count
- OPTN 3
- BOLD 1
- Target Price
- OPTN $9.00
- BOLD N/A
- AVG Volume (30 Days)
- OPTN 41.7K
- BOLD 63.1K
- Earning Date
- OPTN 05-20-2025
- BOLD 05-16-2025
- Dividend Yield
- OPTN N/A
- BOLD N/A
- EPS Growth
- OPTN N/A
- BOLD N/A
- EPS
- OPTN N/A
- BOLD N/A
- Revenue
- OPTN $78,226,000.00
- BOLD N/A
- Revenue This Year
- OPTN $30.49
- BOLD N/A
- Revenue Next Year
- OPTN $13.51
- BOLD N/A
- P/E Ratio
- OPTN N/A
- BOLD N/A
- Revenue Growth
- OPTN 10.20
- BOLD N/A
- 52 Week Low
- OPTN $4.82
- BOLD $1.06
- 52 Week High
- OPTN $20.03
- BOLD $12.26
- Technical
- Relative Strength Index (RSI)
- OPTN 76.15
- BOLD N/A
- Support Level
- OPTN $9.14
- BOLD N/A
- Resistance Level
- OPTN $9.45
- BOLD N/A
- Average True Range (ATR)
- OPTN 0.08
- BOLD 0.00
- MACD
- OPTN -0.07
- BOLD 0.00
- Stochastic Oscillator
- OPTN 80.71
- BOLD 0.00
About OPTN OptiNose Inc.
OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.